<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657031</url>
  </required_header>
  <id_info>
    <org_study_id>EM 2015.13</org_study_id>
    <nct_id>NCT02657031</nct_id>
  </id_info>
  <brief_title>The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine</brief_title>
  <official_title>The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center of Southern Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center of Southern Nevada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy of low dose Ketamine versus Compazine for the control of
      headache in patients presenting to the Emergency Department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, each patient will randomized either to the standard treatment arm to
      receive prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV, OR to the study arm to
      receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. The diphenhydramine or ondansetron
      will be administered first, and immediately afterward the prochlorperazine or Ketamine will
      be administered. The prochlorperazine or Ketamine will be diluted in saline so that the total
      volume is 5 mL, and will be administered over 2 minutes. The diphenhydramine will be diluted
      in saline so that it is 2 mL (the same volume as the ondansetron). Both groups will also
      receive a 500 mL normal saline bolus after the study medications are administered. The ED
      pharmacist will be responsible for preparing the medications, using a double-blind protocol.
      He or she will record which arm the patient was randomized to. Only the pharmacist will have
      access to the randomization records and will not reveal the randomization until the end of
      the study. Emergency providers will be instructed not to administer any rescue medications
      for at least 30 minutes. The electronic medical record order will read &quot;randomized study
      medication&quot; (for the Ketamine or prochlorperazine) and &quot;randomized add-on medication&quot; (for
      the ondansetron or diphenhydramine).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2016</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blind Randomized Clinical Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Following Intervention</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Experiencing Vomiting</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Experiencing Restlessness</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine</intervention_name>
    <description>prochlorperazine 10 mg IV</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Compazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.3 mg/kg IV</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydromine 25 mg IV</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 4 mg IV</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline 500 cc IV Bolus</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Temperature &lt; 100.4Â° F

          -  Diastolic Blood Pressure &lt;104 mm Hg

          -  Normal neurological exam and mormal mental status

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Meningeal signs are present

          -  Acute angle closure glaucoma is suspected.

          -  Head trauma within the previous two weeks

          -  Lumbar puncture within the previous two weeks

          -  Thunderclap onset of the headache

          -  Weight more than 150 kg or less than 40 kg.

          -  Known allergy to one of the study drugs.

          -  History of schizophrenia or bipolar disorder.

          -  History of intracranial hypertension.

          -  Is a prisoner

          -  Patient declined informed consent

          -  Non-English speaking patient.

          -  Attending provider excludes patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Zitek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unviersity of Nevada School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. Natl Health Stat Report. 2008 Aug 6;(7):1-38.</citation>
    <PMID>18958996</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelfand AA, Goadsby PJ. A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room. Neurohospitalist. 2012 Apr 1;2(2):51-59.</citation>
    <PMID>23936605</PMID>
  </results_reference>
  <results_reference>
    <citation>Cicek M, Karcioglu O, Parlak I, Ozturk V, Duman O, Serinken M, Guryay M. Prospective, randomised, double blind, controlled comparison of metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension type headache episodes. Emerg Med J. 2004 May;21(3):323-6.</citation>
    <PMID>15107371</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, Adewunmi V, Campbell C, Solorzano C, Esses D, Bijur PE, Gallagher EJ. A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches. Ann Emerg Med. 2013 Oct;62(4):311-318.e4. doi: 10.1016/j.annemergmed.2013.03.017. Epub 2013 Apr 6.</citation>
    <PMID>23567060</PMID>
  </results_reference>
  <results_reference>
    <citation>Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010 Jul;56(1):1-6. doi: 10.1016/j.annemergmed.2009.11.020. Epub 2010 Jan 4.</citation>
    <PMID>20045576</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003 Jun;41(6):847-53.</citation>
    <PMID>12764341</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989 Feb 24;261(8):1174-6.</citation>
    <PMID>2915441</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P, Radulescu R, Chang E, Hochberg M, Campbell C, Aghera A, Valentin T, Paternoster J, Bijur P, Lipton RB, Gallagher EJ. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008 Oct;52(4):399-406. Epub 2007 Nov 19.</citation>
    <PMID>18006188</PMID>
  </results_reference>
  <results_reference>
    <citation>Callan JE, Kostic MA, Bachrach EA, Rieg TS. Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5.</citation>
    <PMID>18534808</PMID>
  </results_reference>
  <results_reference>
    <citation>Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995 Nov;26(5):541-6.</citation>
    <PMID>7486359</PMID>
  </results_reference>
  <results_reference>
    <citation>Miner JR, Fish SJ, Smith SW, Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001 Sep;8(9):873-9.</citation>
    <PMID>11535479</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedman BW, Hochberg ML, Esses D, Grosberg BM, Rothberg D, Bernstein B, Bijur PE, Lipton RB, Gallagher EJ. Recurrence of primary headache disorders after emergency department discharge: frequency and predictors of poor pain and functional outcomes. Ann Emerg Med. 2008 Dec;52(6):696-704. doi: 10.1016/j.annemergmed.2008.01.334. Epub 2008 Apr 3.</citation>
    <PMID>18387702</PMID>
  </results_reference>
  <results_reference>
    <citation>McCarthy LH, Cowan RP. Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort. Cephalalgia. 2015 Aug;35(9):807-15. doi: 10.1177/0333102414557703. Epub 2014 Nov 3.</citation>
    <PMID>25366551</PMID>
  </results_reference>
  <results_reference>
    <citation>Adams HA. [Mechanisms of action of ketamine]. Anaesthesiol Reanim. 1998;23(3):60-3. Review. German.</citation>
    <PMID>9707750</PMID>
  </results_reference>
  <results_reference>
    <citation>Eghbal MH, Taregh S, Amin A, Sahmeddini MA. Ketamine improves postoperative pain and emergence agitation following adenotonsillectomy in children. A randomized clinical trial. Middle East J Anaesthesiol. 2013 Jun;22(2):155-60.</citation>
    <PMID>24180163</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003 Mar;96(3):789-95, table of contents.</citation>
    <PMID>12598264</PMID>
  </results_reference>
  <results_reference>
    <citation>McGuinness SK, Wasiak J, Cleland H, Symons J, Hogan L, Hucker T, Mahar PD. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med. 2011 Oct;12(10):1551-8. doi: 10.1111/j.1526-4637.2011.01220.x. Epub 2011 Aug 31. Review.</citation>
    <PMID>21880111</PMID>
  </results_reference>
  <results_reference>
    <citation>Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003 Dec;97(6):1730-9. Review.</citation>
    <PMID>14633551</PMID>
  </results_reference>
  <results_reference>
    <citation>Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, Moadebi S. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 10.1111/acem.12229.</citation>
    <PMID>24127709</PMID>
  </results_reference>
  <results_reference>
    <citation>Motov S, Rockoff B, Cohen V, Pushkar I, Likourezos A, McKay C, Soleyman-Zomalan E, Homel P, Terentiev V, Fromm C. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015 Sep;66(3):222-229.e1. doi: 10.1016/j.annemergmed.2015.03.004. Epub 2015 Mar 26.</citation>
    <PMID>25817884</PMID>
  </results_reference>
  <results_reference>
    <citation>Miner JR, Smith SW, Moore J, Biros M. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. Am J Emerg Med. 2007 Jan;25(1):60-4.</citation>
    <PMID>17157685</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <results_first_submitted>October 25, 2017</results_first_submitted>
  <results_first_submitted_qc>December 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Headache, Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This was intended a multi-center (2 sites) study that would have shared redacted data with investigators from both sites, however, site #2 did not receive a data sharing agreement or IRB approval from their institution. So by default the study effectively became a single site study.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Arm</title>
          <description>Prochlorperazine and Diphenhydramine</description>
        </group>
        <group group_id="P2">
          <title>Study Arm</title>
          <description>Ketamine and Ondansetron</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Arm</title>
          <description>This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
Prochlorperazine: prochlorperazine 10 mg IV
Diphenhydromine: Diphenhydromine 25 mg IV
Normal Saline: Normal Saline 500 cc IV Bolus</description>
        </group>
        <group group_id="B2">
          <title>Study Arm</title>
          <description>This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Sailing 500 cc bolus.
Ketamine: Ketamine 0.3 mg/kg IV
Ondansetron: Ondansetron 4 mg IV
Normal Saline: Normal Saline 500 cc IV Bolus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="10.4"/>
                    <measurement group_id="B2" value="32.3" spread="10.3"/>
                    <measurement group_id="B3" value="34.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Scale (VAS) Pain Score, mm</title>
          <description>Scores range from 0 mm (no pain) to 100 mm (maximum pain)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.3" spread="17.7"/>
                    <measurement group_id="B2" value="77.8" spread="14.6"/>
                    <measurement group_id="B3" value="78" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Following Intervention</title>
        <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication.</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Prochlorperazine and Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Study Arm</title>
            <description>Ketamine and Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Following Intervention</title>
          <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="52.7" upper_limit="74.3"/>
                    <measurement group_id="O2" value="43.5" lower_limit="30.2" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication.</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Prochlorperazine and Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Study Arm</title>
            <description>Ketamine and Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety</title>
          <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="32.5"/>
                    <measurement group_id="O2" value="21.2" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication.</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Prochlorperazine and Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Study Arm</title>
            <description>Ketamine and Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea</title>
          <description>Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="34.8"/>
                    <measurement group_id="O2" value="22.9" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Experiencing Vomiting</title>
        <description>Yes/No</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Prochlorperazine and Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Study Arm</title>
            <description>Ketamine and Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Experiencing Vomiting</title>
          <description>Yes/No</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Experiencing Restlessness</title>
        <description>Yes/No</description>
        <time_frame>0-60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>Prochlorperazine and Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Study Arm</title>
            <description>Ketamine and Ondansetron</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Experiencing Restlessness</title>
          <description>Yes/No</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Arm</title>
          <description>Prochlorperazine and Diphenhydramine</description>
        </group>
        <group group_id="E2">
          <title>Study Arm</title>
          <description>Ketamine and Ondansetron</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphoria</sub_title>
                <description>The patients who dropped out of the ketamine group had dysphoria; the patient who dropped out of the prochlorperazine group had akathisia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tony Zitek</name_or_title>
      <organization>University Medical Center Emergency Department</organization>
      <phone>7022247124</phone>
      <email>zitek10@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

